After Trump signed the executive order to expedite the treatment of severe mental illnesses, Psychedelic Pharmaceuticals shares rose

Compass Pathways (CMPS.US) and other psychedelic-related stocks performed well in pre-market trading on Monday. U.S. President Donald Trump signed an executive order on Saturday, calling for expedited access to treatments for patients with severe mental illnesses.

The executive order requires the Director of the U.S. Food and Drug Administration to provide national priority vouchers for "appropriate" psychedelic drugs that have received breakthrough therapy designation for the treatment of severe mental illnesses.

The executive order also directs the Secretary of the U.S. Department of Health and Human Services to allocate USD 50 million through the Advanced Research Projects for Health program.

The U.S. Attorney General has also been instructed to begin reviewing relevant products after successful completion of Phase III clinical trials, in order to reallocate them after receiving FDA approval.

Compass's stock price rose 26% in pre-market trading on Monday; Clearmind Medicine (CMND.US) rose 64%; AtaiBeckley (ATAI.US) rose 25%; Cybin (HELP.US) and GH Research (GHRS.US) both rose 17%; Definium Therapeutics (DFTX.US) rose 12%; Psyence Biomedical (PBM.US) also rose 83%.

This content is generated by AI for general information and reference purposes only and does not constitute any investment advice, solicitation, recommendation, or any form of guarantee. Investment involves risks, and readers should conduct their own research and consult licensed professionals when necessary. AASTOCKS is not responsible for any losses arising from the use or reliance on the above content